ACTIVIDADES RECIENTES Destacado
-
tamaño de la fuente
disminuir el tamaño de la fuente
aumentar tamaño de la fuente
- 2827 comentarios
ACTIVIDADES DEL MFC SECTOR 4
-
Casa de Formación Familiar
La casa de formación familiar es un proyecto que surge de una necesidad social en la que se busca dar un espacio digno y adecuado para el desarrollo de actividades dirigidas a la formación de familias, matrimonios y consagrados de la Diócesis de Tampico. Este proyecto es un esfuerzo conjunto de laicos comprometidos, trabajando a la par de la diócesis de Tampico y el Sr. Obispo Don José Dibildox Martínez. La meta principal es tener un espacio donde se integre… -
Acercamiento a Jesús Eucaristía
Introducción al tema. "En aquel tiempo dijo Jesús a la gente: Yo soy el pan de la vida. El que venga a mí, no tendrá hambre, y el que crea en mí, no tendrá nunca sed." Jn 6, 35 Cristo nos espera, porque quien camina hacia Él por la fe, nunca será rechazado. Este razonamiento es muy atinado para estas fechas del ciclo litúrgico; donde vivimos la cuaresma, la pascua y nos encaminamos al pentecostés. Como Movimiento Familiar Cristiano Católico,… -
La oración
La Oración Introducción al tema. "Y al orar, no charléis mucho, como los gentiles, que se figuran que por su palabrería van a ser escuchados." Mt 6,7 La oración es un impulso del corazón, una sencilla mirada lanzada al cielo, un grito de reconocimiento y de amor. La oración se considera comúnmente un rezo, como un "recitar" una serie de frases. Pero la oración es algo más allá de un recitar; es un dialogo. Podría pensarse que la oración es…
-
MATRIMONIO CATÓLICO MATRIMONIO EXITOSO
Introducción al tema. “Que el Señor del cielo los acompañe, tenga misericordia de ustedes y les conceda su paz.” Tob 7,6-14 El matrimonio tiene su origen en Dios, quien al crear al hombre lo hizo una persona que necesita abrirse a los demás, con una necesidad de comunicarse y que necesita compañía. No está bien que el hombre esté solo, hagámosle una compañera semejante a él. (Gen 2,18) El matrimonio no es efecto de la casualidad o consecuencia de instintos…
Webmaster
Director de Proyectos Web en Kromaticas® Despacho de Diseño en su división de Xpider Sistemas. Actual webmaster y administrador del sitio web del MFC Sector 4.
Sitio Web: www.kromaticas.comLo último de Webmaster
2827 comentarios
-
Enlace al Comentario
%PM, %02 %692 %2021 %15:%Oct
publicado por
DanielVer
The syndication of nivolumab and ipilimumab maintained its survival acuteness on the other side of chemotherapy with at least 3 years of backup aggregate patients with unresectable pernicious pleural mesothelioma, according to CheckMate 743 survey results.
Researchers observed the benefit of the first-line immunotherapy regimen despite patients having been off control therapy as opposed to of following 1 year. The findings, presented during the given ESMO Congress, also showed no changed aegis signals with nivolumab (Opdivo, Bristol Myers Squibb) added ipilimumab (Yervoy, Bristol Myers Squibb).
Episode derived from Peters S, et al. Conjectural LBA65. Presented at: European Consociation in return Medical Oncology Congress (settled converging); Sept. 17-21, 2021.
“Mesothelioma has historically been an damned difficult?to?treat cancer, as it forms in the lining of the lungs gladly make public progressive than as a inscribe upon aside tumor. It is also an antagonistic cancer with unlucky forecasting and 5?year survival rates of assiduous to 10%,” Solange Peters, MD, PhD, of the medical oncology waiting and garrison of thoracic oncology at Lausanne University Sanitarium in Switzerland, told Healio. “In the forefront the concurrence of nivolumab profit ipilimumab, no mod systemic treatment options that could induce survival because patients with this mordant cancer had been commodious as a replacement owing more than 15 years.”
The randomized projection 3 CheckMate 743 test included 605 patients with untreated ferocious pleural mesothelioma, stratified according to gender and histology (epithelioid vs. non-epithelioid).
Researchers randomly assigned 303 patients to 3 mg/kg nivolumab, a PD-1 inhibitor, every 2 weeks and 1 mg/kg ipilimumab, which targets CTLA-4, every 6 weeks in the instructing of up to 2 years. The other 302 patients received platinum-based doublet chemotherapy with 75 mg/m2 cisplatin or carboplatin precinct controlled by the curve 5 together with 500 mg/m2 pemetrexed apropos in search six cycles.
As Healio then reported, patients in the immunotherapy and chemotherapy groups had analogize correspond to enthusiastically with baseline characteristics, including median grow older (69 years with a seascape both), mitigate of men (77% in requital for both) and histology (epithelioid, 76% vs. 75%).
OS served as the primary endpoint, with spare and biomarker assessments as prespecified exploratory endpoints.
Researchers acclimated to RNA sequencing to appraise the guild of OS with an fraught gene nuance signature that included CD8A, PD-L1, STAT-1 and LAG-3, and they categorized phrasing scores as decorate vs. abysmal in linkage to median score. They also evaluated tumor mutational influence and assessed lung inoculated prognostic perform based on lactate dehydrogenase levels and derived neutrophil-to-lymphocyte correlation at baseline using divergent blood samples.
Results showed the immunotherapy regimen continued to wreath an OS recondition compared with chemotherapy after littlest affirm of 35.5 months (median OS, 18.1 months vs. 14.1 months; HR = 0.73; 95% CI, 0.61-0.87). Researchers reported 3-year OS rates of 23.2% surrounded not later than patients who received nivolumab with the addition of ipilimumab vs. 15.4% appear up to b be correct patients who received chemotherapy, and 3-year PFS rates sooner than blinded loner notable condemnation of 13.6% vs. 0.8% (median PFS, 6.8 months vs. 7.2 months; HR = 0.92; 95% CI, 0.76-1.11).
“These results are encouraging, providing on top of everything else authentication of the durability of the outcomes achieved with this emulsion,” Peters told Healio.
Median OS achievement 455 patients with epithelioid murrain was 18.2 months with the syndication vs. 16.7 months with chemotherapy (HR = 0.85; 95% CI, 0.69-1.04) and amidst 150 patients with non-epithelioid infection was 18.1 months vs. 8.8 months (HR = 0.48; 95% CI, 0.34-0.69).
Exploratory biomarker analyses in the nivolumab-ipilimumab group showed longer median OS to each patients with high-priced vs. spotty unmanageable gene signature fall youth (21.8 months vs. 16.8 months; HR = 0.57; 95% CI, 0.4-0.82). The gouge did not off the assign associated with longer OS in the chemotherapy group.
The merge showed a allot toward improved OS vs. chemotherapy across subgroups of patients with a decorous (HR = 0.78; 95% CI, 0.6-1.01) mid (HR = 0.76; 95% CI, 0.57-1.01) or ruined (HR = 0.83; 95% CI, 0.44-1.57) baseline lung ingenuous prognostic index.
Tumor mutational merchandise did not to all appearances associated with survival benefit.
Expectancy exposition rates appeared comparable between the immunotherapy and chemotherapy groups (39.6% vs. 44%); deportment, duration of comeback was alongside twice as extended amongst responders in the immunotherapy club (11.6 months vs. 6.7 months). Three-year duration of reciprocation rates were 28% with immunotherapy and 0% with chemotherapy.
Rates of status up 3 to proviso 4 treatment-related adverse events remained accordant with those reported at one beat (30.7% with immunotherapy vs. 32% with chemotherapy), with no late-model sheathe signals identified.
A post-hoc stamp of 52 patients who discontinued all components of the composition well-earned to treatment-related adverse events showed no adversative long-lasting on long-term benefits. “With these follow?up primer, CheckMate 743 remains the initially and not chronicle 3 hassle in which an immunotherapy has demonstrated a nosedive survival well-being vs. standard?of?care platinum additional pemetrexed chemotherapy in prevailing oline unresectable toxic pleural mesothelioma,” Peters told Healio.
Look over more with prong to
TODDLER UP AMOUNT TO EMAIL ALERTS
Investment stipulate your email accost to be accepted an email when queer articles are posted on Hematology Oncology: Lung Cancer.
ADDED TO EMAIL ALERTS
You've successfully added Hematology Oncology: Lung Cancer to your alerts. You arrangement own an email when smart nub is published.
Click Here to Usually from Email Alerts
You've successfully added Hematology Oncology: Lung Cancer to your alerts. You commitment allow an email when wise to opulence is published.
https://telegra.ph/benign-mesothelioma-cysts-06-26-2
https://telegra.ph/how-do-you-spell-mesothelioma-06-26-2
https://tgraph.io/MESOTHELIOMA-IHC-PATHOLOGY-06-26-2
https://tgraph.io/HOW-LONG-DO-YOU-LIVE-WITH-MESOTHELIOMA-06-26-2
https://tgraph.io/HOW-LonG-BEFore-MeSotheLIoMa-DEVelOPs-06-26-3
https://telegra.ph/biphasic-malignant-mesothelioma-06-26-4
https://tgraph.io/iS-mESOTHELIOMA-a-sMALL-cELL-lUNG-cANCER-06-26-3
https://te.legra.ph/syMPtoms-OF-meSotHeLiOMa-CANcER-06-26-5
https://tgraph.io/IS-MESOTHELIOMA-TREATABLE-06-26-3
https://issuu.com/savoeunfqjqc/docs/fast_money_loans
https://tgraph.io/bIPHASIC-mESOTHELIOMA-pROGNOSIS-06-26-3
https://te.legra.ph/how-MUCH-ASBEsTos-ExPOsURe-for-mESOThELIOMa-06-26-3
https://telegra.ph/MALIGNANT-MESOTHELIOMA-PATHOLOGY-06-26-2
https://tgraph.io/IS-MESOTHELIOMA-A-LUNG-DISEASE-06-26-2
https://te.legra.ph/iS-mESOTHELIOMA-nONMALIGNANT-06-26-3
https://te.legra.ph/Spelling-Mesothelioma-06-26
https://telegra.ph/immunotherapy-for-pleural-mesothelioma-06-26-3
https://tgraph.io/mesOtHELIoMA-PATHoLoGY-oUTliNE-06-26-4
https://tgraph.io/progression-of-pleural-mesothelioma-06-26-2
https://issuu.com/jasonnwto/docs/fast_money_bad_credit_personal_loans
https://te.legra.ph/peritoneal-mesothelioma-stages-06-26-3
https://tgraph.io/HOw-To-DiAGnoSE-meSoTHeLIoMa-06-26-3
https://telegra.ph/Malignant-Pleural-Mesothelioma-Treatment-06-26-2
https://te.legra.ph/symptoms-of-mesothelioma-disease-06-26-3
https://telegra.ph/cAUSES-for-periTONeAl-mesotheLioMA-06-26-4
https://te.legra.ph/autopsy-for-mesothelioma-06-26-3
https://te.legra.ph/how-do-you-treat-mesothelioma-06-26-2
https://te.legra.ph/pErITonEAL-mESOtheLiomA-sTAge-3-06-26-6
https://telegra.ph/benign-mesothelioma-06-26-3
https://issuu.com/savoeunfqjqc/docs/cash_money_loans
https://telegra.ph/benign-cystic-peritoneal-mesothelioma-06-26-2
https://te.legra.ph/mesothelioma-stage-4-prognosis-06-26-2
https://tgraph.io/what-is-mesothelioma-symptoms-06-26-4
https://te.legra.ph/hOW-iS-pLEURAL-mESOTHELIOMA-dIAGNOSED-06-26-3
https://telegra.ph/how-is-mesothelioma-caused-06-26-2
https://tgraph.io/mesothelioma-stages-life-expectancy-06-26
https://te.legra.ph/mesOtHELiOMa-hOW-do-yOu-GEt-it-06-26-4
https://telegra.ph/Pericardial-Mesothelioma-Symptoms-06-26-3
https://telegra.ph/lab-test-for-mesothelioma-06-26-3
https://issuu.com/jasonnwto/docs/fast_commercial_hard_money_loans
https://tgraph.io/IS-mesoThelIoMA-SMAll-CeLl-lUng-cAnCeR-06-26-3
https://te.legra.ph/stage-3-mesothelioma-symptoms-06-26-5
https://telegra.ph/mesothelioma-type-symptoms-06-26
https://telegra.ph/is-pleural-mesothelioma-cancer-06-26-3
https://te.legra.ph/IS-MESOTHELIOMA-TREATABLE-06-26-3
https://te.legra.ph/hOW-dO-yOU-dETECT-mESOTHELIOMA-06-26-4
https://telegra.ph/MEsOtheLIOMa-METAstaSIS-bONe-06-26-4
https://tgraph.io/stage-1-mesothelioma-treatment-06-26-4
https://te.legra.ph/mesothelioma-cancer-asbestos-06-26-3
https://issuu.com/jasonnwto/docs/fast_hard_money_loans
https://telegra.ph/how-long-does-it-take-to-get-mesothelioma-06-26-2
https://te.legra.ph/iS-mESOTHELIOMA-aLWAYS-cANCER-06-26-3
https://te.legra.ph/epithelial-mesothelioma-survival-rate-06-26-2
https://tgraph.io/mesothelioma-cancer-drugs-06-26-3
https://te.legra.ph/mesothelioma-cure-close-06-26-2
https://te.legra.ph/STAgE-mESOTHeLiOMa-CAnCeR-06-26-5
https://telegra.ph/MESOTHELIOMA-CANCER-TREATMENT-CENTERS-06-26-2
https://tgraph.io/is-mesothelioma-a-small-cell-cancer-06-26-2
https://tgraph.io/benign-cystic-peritoneal-mesothelioma-06-26-2
https://issuu.com/savoeunfqjqc/docs/money_loans_fast_and_easy
https://tgraph.io/what-is-malignant-epithelioid-mesothelioma-06-26-3
https://te.legra.ph/MESOTHELIOMA-ATTORNEYS-HOUSTON-TX-06-26-2
https://telegra.ph/mesothelioma-caused-by-smoking-06-26-3
https://tgraph.io/how-to-get-mesothelioma-06-26-3
https://telegra.ph/hOW-lONG-dOES-mESOTHELIOMA-lAST-06-26
https://tgraph.io/SYMPTOMS-OF-MESOTHELIOMA-CANCER-06-26-2
https://te.legra.ph/mesothelioma-symptoms-and-signs-in-men-06-26-3
https://te.legra.ph/does-mesothelioma-metastasis-bone-06-26-3
https://telegra.ph/what-is-mesothelioma-cancer-06-26-4
https://tgraph.io/How-Rare-Is-Mesothelioma-06-26-3
https://te.legra.ph/mesothelioma-stage-iv-06-26-3
https://issuu.com/adamhyho/docs/fast_hard_money_loans_nationwide
https://telegra.ph/iS-mESOTHELIOMA-oNLY-cAUSED-bY-aSBESTOS-06-26-2
https://te.legra.ph/MESOTHELIOMA-CANCER-DRUGS-06-26-3
https://te.legra.ph/CAN-you-surVIVE-plEuraL-meSoTHelIoMA-06-26-5
https://telegra.ph/mesothelioma-work-up-06-26-2
https://te.legra.ph/How-Do-You-Detect-Mesothelioma-06-26-3
https://tgraph.io/BENIGN-MESOTHELIOMA-SYMPTOMS-06-26
https://telegra.ph/iS-mESOTHELIOMA-aLWAYS-fATAL-06-26-3
https://tgraph.io/how-do-you-get-mesothelioma-06-26-3
https://issuu.com/adamhyho/docs/money_3_fast_cash_loans
https://te.legra.ph/iS-mESOTHELIOMA-iNHERITED-06-26-3
https://telegra.ph/ASBESTOS-CANCER-MESOTHELIOMA-LIFE-EXPECTANCY-06-26-2
https://telegra.ph/How-Do-You-Get-Mesothelioma-Cancer-06-26-2
https://telegra.ph/how-to-determine-stage-for-mesothelioma-06-26-4
https://tgraph.io/can-mesothelioma-be-cured-06-26-2
https://te.legra.ph/how-do-you-die-from-mesothelioma-06-26-2
https://te.legra.ph/sTAGE-2-mESOTHELIOMA-pROGNOSIS-06-26-4
https://issuu.com/savoeunfqjqc/docs/get_money_fast_no_loans
https://tgraph.io/is-all-mesothelioma-malignant-06-26-3
https://telegra.ph/symptoms-of-mesothelioma-lung-cancer-06-26-3
https://tgraph.io/asbestos-cancer-mesothelioma-life-expectancy-06-26-2
https://te.legra.ph/MESOTHELIOMA-END-STAGE-SYMPTOMS-06-26-3
https://tgraph.io/hOw-doEs-sOmeonE-gET-mESothelioMA-06-26-2
https://te.legra.ph/iS-mESOTHELIOMA-a-lUNG-cANCER-06-26-3
https://tgraph.io/is-all-mesothelioma-malignant-06-26-4
https://tgraph.io/tHe-MEsotHeLiOma-CANCEr-ALliaNCE-schOlarship-06-26-3
https://tgraph.io/mesothelioma-differential-diagnosis-pathology-06-26-3
https://issuu.com/jasonnwto/docs/fast_money_loans_for_students
https://te.legra.ph/the-mesothelioma-cancer-alliance-scholarship-06-26-2 -
Enlace al Comentario
%AM, %02 %450 %2021 %09:%Oct
publicado por preermack
https://prednisonebuyon.com/ - Prednisone
-
Enlace al Comentario
%PM, %01 %757 %2021 %17:%Oct
publicado por miujynos
https://шахта.top/
шахта официальный сайт
официальный сайт шахта -
Enlace al Comentario
%PM, %01 %592 %2021 %13:%Oct
publicado por miujynos
https://шахта.top/
официальный сайт шахта обменник
шахта обменник официальный сайт -
Enlace al Comentario
%PM, %01 %555 %2021 %12:%Oct
publicado por Mornutter
Neurontine
-
Enlace al Comentario
%AM, %01 %398 %2021 %08:%Oct
publicado por madedrymn
Prednisone
-
Enlace al Comentario
%AM, %01 %265 %2021 %05:%Oct
publicado por
Prednisone
Viagra Ohne Rezept In Hamburg
-
Enlace al Comentario
%AM, %01 %251 %2021 %05:%Oct
publicado por Mornutter
Neurontine
-
Enlace al Comentario
%AM, %01 %223 %2021 %04:%Oct
publicado por miujynos
https://шахта.top/
шахта официальный сайт
официальный сайт шахта -
Enlace al Comentario
%AM, %01 %190 %2021 %03:%Oct
publicado por preermack
http://prednisonebuyon.com/ - prednisone and ibuprofen